Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


FDA approves first app for substance abuse disorders

The US Food and Drug Administration has approved a mobile app for therapeutic purposes for the first time.



The reSET app is a cognitive behavioural therapy-based tool intended to be used in conjunction with standard counselling

The US Food and Drug Administration (FDA) has approved a mobile app for therapeutic purposes for the first time.

The reSET app is a cognitive behavioural therapy-based tool intended to help those with substance use disorders remain abstinent and engaged with their outpatient therapy. It is approved for use in alcohol, cocaine, marijuana and stimulant substance use disorders.

“This is an example of how innovative digital technologies can help provide patients access to additional tools during their treatment,” said Carlos Peña, from the FDA’s center for devices and radiological health.

“More therapy tools means a greater potential to help improve outcomes, including abstinence, for patients with substance use disorder.”

The app is modular and teaches patients skills for achieving and maintaining abstinence. It also allows the patient’s medical provider to access data on self-reported substance use, triggers, cravings and outcomes.

The app is not intended as a stand-alone treatment, but to be used alongside outpatient therapy and a contingency management system that incentivises and rewards patients for their adherence to their treatment plan.

reSET’s creators, a startup called Pear Therapeutics, conducted a randomised trial of a desktop-based version of their app involving 399 people with substance use disorders. They showed that 40.3% of those who used reSET alongside standard face-to-face counselling were abstinent at 12 weeks compared with 17.6% of those who received standard counselling alone.

The company said it plans to trial a version of the software for opioid addiction, and are also working on products for use in schizophrenia, combatting post-traumatic stress disorder and generalised anxiety disorder.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203600

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • mobile-phone-app-finger-15

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.